Chronic Inflammation Associated with Hepatitis C Virus Infection Perturbs Hepatic Transforming Growth Factor Beta Signaling, Promoting Cirrhosis and Hepatocellular Carcinoma
Overview
Authors
Affiliations
Unlabelled: Many patients with chronic hepatitis caused by hepatitis C virus (HCV) infection develop liver fibrosis with high risk for hepatocellular carcinoma (HCC), but the mechanism underling this process is unclear. Conversely, transforming growth factor beta (TGF-beta) activates not only TGF-beta type I receptor (TbetaRI) but also c-Jun N-terminal kinase (JNK), which convert the mediator Smad3 into two distinctive phosphoisoforms: C-terminally phosphorylated Smad3 (pSmad3C) and linker-phosphorylated Smad3 (pSmad3L). Whereas the TbetaRI/pSmad3C pathway suppresses epithelial cell growth by upregulating p21(WAF1) transcription, JNK/pSmad3L-mediated signaling promotes extracellular matrix deposition, partly, by upregulating plasminogen activator inhibitor 1 (PAI-1). We studied the domain-specific Smad3 phosphorylation in biopsy specimens representing chronic hepatitis, cirrhosis, or HCC from 100 patients chronically infected with HCV, and correlated Smad3 phosphorylation with clinical course. As HCV-infected livers progressed from chronic hepatitis through cirrhosis to HCC, hepatocytic pSmad3L/PAI-1 increased with fibrotic stage and necroinflammatory grade, and pSmad3C/p21(WAF1) decreased. Of 14 patients with chronic hepatitis C with strong hepatocytic pSmad3L positivity, 8 developed HCC within 12 years; only 1 of 12 showing little pSmad3L positivity developed HCC. We further sought molecular mechanisms in vitro. JNK activation by the pro-inflammatory cytokine interleukin-1beta stimulated the pSmad3L/PAI-1 pathway in facilitating hepatocytic invasion, in the meantime reducing TGF-beta-dependent tumor-suppressive activity by the pSmad3C/p21(WAF1) pathway.
Conclusion: These results indicate that chronic inflammation associated with HCV infection shifts hepatocytic TGF-beta signaling from tumor-suppression to fibrogenesis, accelerating liver fibrosis and increasing risk for HCC.
Liu F, Liu B, Xu S, Ni Y, Liu X Endocr J. 2024; 72(1):53-67.
PMID: 39358210 PMC: 11778391. DOI: 10.1507/endocrj.EJ24-0317.
Galasso L, Cerrito L, Maccauro V, Termite F, Mignini I, Esposto G Int J Mol Sci. 2024; 25(13).
PMID: 39000296 PMC: 11241080. DOI: 10.3390/ijms25137191.
Yan W, Rao D, Fan F, Liang H, Zhang Z, Dong H Front Oncol. 2024; 14:1407434.
PMID: 38962270 PMC: 11220127. DOI: 10.3389/fonc.2024.1407434.
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease.
He Q, He W, Dong H, Guo Y, Yuan G, Shi X Cell Commun Signal. 2024; 22(1):346.
PMID: 38943171 PMC: 11214243. DOI: 10.1186/s12964-024-01720-9.
Hepatitis C Virus Dysregulates Polyamine and Proline Metabolism and Perturbs the Urea Cycle.
Zakirova N, Khomich O, Smirnova O, Molle J, Duponchel S, Yanvarev D Cells. 2024; 13(12.
PMID: 38920664 PMC: 11201506. DOI: 10.3390/cells13121036.